FDA moves to exclude weight loss drugs from compounding chemicals list
The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- from its 503B bulks list.
Original Source
Read the full article at Upi →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.